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Abstract
Background: Breast cancer (BC) is a major public health problem, with rising incidence in many
regions of the globe. Although mortality has recently dropped in developed countries, death rates
are still increasing in some developing countries, as seen in Brazil. Among the reasons for this
phenomenon are the lack of structured screening programs, a long waiting period between
diagnosis and treatment, and lack of access to health services for a large proportion of the Brazilian
population.
Methods and design: Since 2004, an intervention study in a cohort of women in Southern Brazil,
denominated Porto Alegre Breast Health Intervention Cohort, is being conducted in order to test
the effectiveness and cost-effectiveness of a model for BC early detection and treatment. In this
study, over 4,000 women from underserved communities aged 40 to 69 years are being screened
annually with mammography and clinical breast examination performed by a multidisciplinary team,
which also involves nutritional counseling and genetic cancer risk assessment. Risk factors for BC
development are also being evaluated. Active search of participants by lay community health
workers is one of the major features of our program. The accrual of new participants was
concluded in 2006 and the study will last for 10 years. The main goal of the study is to demonstrate
significant downstaging of BC in an underserved population through proper screening, attaining a
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BMC Public Health 2009, 9:83 http://www.biomedcentral.com/1471-2458/9/83higher rate of early-stage BC diagnoses than usually seen in women diagnosed in the Brazilian Public
Health System. Preliminary results show a very high BC incidence in this population (117 cases per
100,000 women per year), despite a low prevalence of classical risk factors.
Discussion: This study will allow us to test a model of BC early diagnosis and treatment and
evaluate its cost-effectiveness in a developing country where the mortality associated with this
disease is very high. Also, it might contribute to the evaluation of risk factors in a population with
a different ethnic background from that studied in developed countries. If our model is proven
effective, it may be replicated in other parts of the globe where BC is also a major public health
problem.
Background
Breast cancer as a major public health problem
Breast cancer (BC) incidence rates have increased signifi-
cantly worldwide, and today is the most common non-
skin cancer in women in almost all parts of the globe. The
incidence is higher in the United States and Northern
Europe, intermediate in Southern and Eastern Europe and
South America, and lower in Asia [1].
Although BC incidence rates are still increasing in devel-
oped countries, BC mortality rates have declined in recent
years in these nations, what can be explained by greater
breast cancer awareness, by the guarantee of health care
access and by the adoption of public policies towards
early tumor detection. In countries who have successfully
implemented nationwide mammography screening pro-
grams, such as the United Kingdom [2], the Netherlands
[3] and Sweden [4,5], the mortality rates have dropped by
at least 20%.
In contrast, in Brazil and other developing countries, both
mortality and incidence rates have steadily increased in
recent years. For example, the age-standardized mortality
(ASM) related to BC in Brazil has grown from 10.74 per
100,000 women in 2000 to 12.32 in 2005 [6], which
probably reflects the delay in diagnosis: almost half of the
BC cases in Brazil are diagnosed in stages III and IV [7-9].
When breast tumors in Brazil are analyzed according to
their staging, mortality is similar to studies conducted in
developed countries, supporting the idea that late diagno-
sis is one of the main causes of the high case fatality rate
observed in the country [10].
The State of Rio Grande do Sul (RS, the southernmost
state in the country) presents the second highest breast
cancer incidence rate in the country, with an estimated
rate of 85.50 new cases per 100,000 women in 2008 – a
number comparable to the USA and North Europe. The
State's capital, Porto Alegre, has an even higher BC inci-
dence rate, with 119.72 new cases per 100,000 women
projected for the current year [11].
Breast cancer screening in Brazil
In Brazil, approximately 75% of the population has access
to health care only through the Brazilian Public Health
System (PHS) [12], which is therefore responsible for the
provision of breast health care to the majority of the pop-
ulation. The initial health care is provisioned in primary
care, by the basic healthcare units (BHUs), the first access
to health provision in the country, since the referral for
other levels of care is their attribution. In our city, Porto
Alegre, there are 87 BHUs, for a total population of 1.45
million inhabitants. This infrastructure is one of the most
organized primary care setting in the whole country.
In Brazil, the current national recommendation for breast
cancer screening calls for mammography at two-year
intervals, targeted at women between the ages of 50 and
69 years [13]. These recommendations are not in accord-
ance with those published by the Brazilian Society of
Breast Disease [14], which recommends annual screening
between the ages of 40 and 69 years.
Although the government guideline containing these rec-
ommendations has been published in 2004, there is not
actually a national screening program, since there is no
provision of financing nor training of health care profes-
sionals capable to provide service to all eligible women
between ages 50 and 69 years. In the areas of the city of
Porto Alegre included in this project, there used to be no
mammographic reference service. Women with breast
symptoms used to be referred to the city central area,
where they were offered the services of a breast specialist
necessary for diagnostic procedures (mammography,
ultrasound, core biopsy) and treatment, with very long
waiting times for each step of the process. A national sur-
vey conducted in 2003 confirms the lack of a structured
screening program in the country, showing that 49.7% of
women above the age of 50 have never been submitted toPage 2 of 8
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exam, 18% did it more than 2 years ago [15].
The Porto Alegre Breast Health Intervention Cohort
Considering the above, the Associação Hospitalar Moin-
hos de Vento, in a partnership with the City Health
Department of Porto Alegre and a non-profit organization
(Breast Institute of Rio Grande do Sul), initiated a pro-
spective breast cancer screening study, denominated Porto
Alegre Breast Health Intervention Cohort (NMPOA –
Núcleo Mama Porto Alegre). The two primary objectives
of this project are:
(1) To test the effectiveness of a centrally structured
mammography screening and early treatment pro-
gram, based on active women search, close contact
with the BHU, promoting a multidisciplinary and
humanized care for an underserved population from a
developing country;
(2) To verify the profile of breast cancer risk factors in
the sample studied, evaluating the frequency and pos-
sible contribution of established risk factors and
attempting to identify new ones.
A secondary objective of the study is the estimation of the
cost-effectiveness of such a program.
Methods and design
Study design, setting and participants
The NMPOA project is a breast cancer screening and early
treatment program, with evaluation of risk factors for
breast cancer in an intervention cohort. From April 2004
through March 2006, 9,218 women aged 15 years or older
visiting one of the 19 participating BHUs from Porto Ale-
gre were evaluated in a cross-sectional study, which
included: (1) an entry form questionnaire regarding risk
factors for breast cancer – including family history (FH) of
cancer – and presence of breast symptoms, and (2) breast
examination by a trained professional (nurse or medical
doctor). All patients with breast complaints or an abnor-
mal physical exam were referred to NMPOA for further
evaluation. Women between 40 and 69 years of age were
invited to participate in the screening cohort. Women
without symptoms and outside the targeted age group
were advised to attend the BHU once a year for physical
examination. Figure 1 displays the evaluation flowchart.
Women who participated in the cross-sectional study and
complete 40 years of age during the project period, which
was set to last until 2014, are also being invited to join the
screening cohort.
The accrual was done at the participating BHUs both
actively (i.e., lay health community workers inviting
women in their own homes) and passively (women that
attended the BHU for any reason being invited to the
project). Although women from all ages above 15 could
be enrolled in the cross-sectional study, the main empha-
sis was the invitation of women between the ages of 40
and 69 years, since that would be the group which would
enter the screening cohort. The total number of women
between 40 and 69 years old in the region was approxi-
mately 16,000, according to the most recent national cen-
sus (year 2000), and the accrued number was about 4,000
in this age range.
The screening program is based on annual mammogra-
phies in women between the ages of 40 and 69 years,
which are always preceded by physical examination per-
formed by a breast surgeon or a trained nurse. One of the
main features of the program is its close control of the fre-
quency of visits, based on a computer system that gener-
ates monthly reports on the due dates of all participants.
The close contact and continuous feedback to the BHUs
professionals guarantees that this strategy is put into prac-
tice with maximum effort, in order to achieve optimal
adherence to the screening program.
The proposal of the NMPOA project includes the perform-
ance of all clinical, imaging and pathology exams, as well
as clinical visits and surgical treatment, in the same center.
The health care approach is multi-disciplinary, including
nurses, breast surgeons and a nutritionist. All mammogra-
phies are performed on the same day of the clinical visit,
and they remain stored at the center. This integration of
screening, diagnosis and treatment in the same center is
an effort to shorten the time of delivery of appropriate
treatment in each newly diagnosed breast cancer case.
All mammographic exams done at NMPOA are inter-
preted only by radiologists who are specialized in breast
cancer and follow rigorous international standards of
Flowchart of Patients in the Studyigure 1
Flowchart of patients in the study. BHU: Basic Health 
Unit; NMPOA: Núcleo Mama Porto Alegre.
BHU evaluation and 
data collection
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using density and risk criteria, purposed by the BI-RADS
(Breast Imaging Report and Data System) classification
[16]. Women with a mammogram classified as BI-RADS 3
are asked to return in six months for a new exam. If a
mammogram is classified as BI-RADS 0, a complementary
exam is necessary, and if the result is a BI-RADS 4 or 5
image, a biopsy is performed. Patients who have a diagno-
sis of breast cancer are operated in the same center.
The imaging screening consists of mammograms in
patients older than 40 and ultrasound starting at an age 10
years younger than the relative's age when diagnosed with
BC, not starting before the age of 25 (that is, if the relative
was diagnosed before the age of 35, the patient would
start ultrasound only when she was 25).
Participants of the cross-sectional study older than 18
years answering positively to at least one of the FH ques-
tions described below were referred to genetic cancer risk
assessment. If the risk assessment yielded moderate or
high genetic risk (estimated lifetime breast cancer risks
greater than 20% or a family history suggestive of a hered-
itary breast cancer syndrome), the participant was invited
to attend clinical visits and imaging screening at the
NMPOA center, being followed by breast physicians and
geneticists every six months. The main goals of the genetic
evaluations are to determine: (1) the prevalence of a first-
degree FH of cancer and characterize the type of cancer,
age at diagnosis and relationship of the cancer-affected
relative to the proband; (2) the lifetime breast cancer risk
estimates in women attending the cohort and reporting a
family history of breast and other cancers; (3) the preva-
lence of hereditary breast cancer phenotypes in a popula-
tion-based sample of women in Latin America; (4) the
contribution of germline mutations in known breast can-
cer predisposition genes among women from the cohort
reporting a FH of cancer and fulfilling criteria for the clin-
ical diagnosis of a breast cancer predisposition syndrome.
Preliminary reports on the results of the genetic evalua-
tion have been published elsewhere [17].
Measurements and data collection
The questions regarding FH in the cross-sectional study
focused on features that have been associated with an
increased likelihood of clinically significant BRCA muta-
tions, such as early-onset, bilateral or male breast cancer,
multiple primary cancers of the breast and ovary, first-
degree or multiple-case family history of breast or ovarian
cancer. In addition, a question about FH of BC and/or
colon cancer was included due to a previous suggestion of
a higher than expect prevalence of such association in can-
cer genetic clinics of Porto Alegre.
Additional risk factors evaluated in the cross-sectional
study included smoking, obesity, alcohol consumption
and history of breast diseases. Current smokers were
defined as those who smoked at least one cigarette per
day; never smokers those who have never tried a cigarette
in their life; and former smoker were defined as those who
had stopped smoking for at least one year. Educational
level of the participants (as a proxy of social status) was
also inquired, and was measured by the years of school-
ing.
For the approximately 4,000 already registered women in
the annual mammographic screening, a complete clinical
form was filled when they joined the cohort, containing
gynecological-obstetric data (such as number of pregnan-
cies and hormone use), family history, medical history
and physical exam, which includes anthropometric meas-
urements and breast examination. Every time the partici-
pant returns for clinical evaluation and annual
mammography, the answers are updated, since many of
these risk factors are dynamic. BI-RADS data from all
mammographies, including density score, are also stored.
If a tumor is diagnosed, all data concerning staging,
pathology report, hormone receptors and both surgical
and oncological treatment are registered.
Participants who do not wish to continue in the screening
program (or enter it, in the case of women reaching the
age of 40) are requested to fill a form with the motive of
withdrawal. This is also being recorded, in order to under-
stand reasons for non-compliance, a major problem in
Brazil [15,18-22].
For the patients who need complimentary investigation
(other imaging modalities and biopsies), as well as in
women who undergo surgical and oncological treatment
for cancer, length between each step of care is been
recorded. We intend to compare these data with other
national registries in the PHS [23] in order to have a
promptness and efficiency indicator of our model of care.
Power calculations
The best parameter to show the effectiveness of our pro-
gram would be breast cancer associated mortality. How-
ever, considering the very long breast cancer related death
survival in asymptomatic women (especially in effective
screening programs, where the detected cancers tend to
have an excellent prognosis), and taking into account the
well established relationship between tumor staging and
survival [24], we chose this variable as the primary end-
point of our program. Since breast cancer survival has a
significant drop even in stage II cases, we considered only
staging equal or less than stage I as a favorable outcome to
the screening program.Page 4 of 8
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that the staging of all breast cancers diagnosed during the
study period in our city in a similar population (that is, in
women from the same age group seen at public hospitals)
would be suitable. These data are available upon request
in the City Health Department. The total number of
women between 40 and 69 years today in Porto Alegre is
247,000 [25], of which 75% (185,000) are estimated to
have all their health care provided by the PHS [12]. We
have already enrolled more than 4,000 women in the
screening project, and, considering the expected number
of women entering the cohort as they reach the age of 40
years, we estimate that we will have an average number of
4,250 women during the 10 year duration of the project.
The correct number of the comparison group is therefore
180,750 women (185,000 minus 4,250), yielding a rate
of circa 40 to 1 between the two samples. Applying the
estimation of 119 breast cancer cases per 100,000 to our
city in the current year [11], the number of cases in
NMPOA would be 5 per year. Considering a 70% rate of
tumor staging greater or equal to II in the city [9], it would
be necessary to have 45 cases in the NMPOA cohort to
show a 35% reduction in this rate, with an alfa = 0.05 and
90% power. We decided to achieve a 10% higher number
of cases to overcome possible incorrect estimates in this
calculation. Therefore, we decided to set the study period
to ten years, in order to achieve 50 cancer cases in our
cohort.
Statistical analysis
The proportion of cases at or below stage I in the NMPOA
cohort and the same proportion in the city will be com-
pared by the Fisher's exact test. Continuous variables, like
the time frames between the steps of care, will be com-
pared with Student's t-test. We are also planning to per-
form a cost-effectiveness analysis of this intervention, in
which a Markov model will be employed.
Ethical issues
This project was approved by the ethical review board
(ERB) of the City Health Department and of Associação
Hospitalar Moinhos de Vento. The genetics project was
also approved by the ERB from Hospital de Clínicas de
Porto Alegre, where all biological material are stored. All
subjects were provided a copy of the written consent
before study entry and were assured of their anonymity
and confidentiality of data collected.
Characteristics of the study population at baseline
The screening cohort has already enrolled 4,037 women.
Considering the number of women registered in the cross-
sectional study who are reaching the age of 40 and will
enter the cohort until the year 2014, this number will
probably reach 4,500 until the end of the project.
Table 1 shows the baseline characteristics of the screening
cohort. This population has a high average number of
pregnancies (3 or more in over 60% of women), a low
percentage of late menopause and low rate of hormone
replacement therapy use. Women in our cohort have their
first delivery at a young age (21.4 ± 5.1 years). The pres-
ence of relatives with any type of cancer is high (33.7%),
and the prevalence of overweight and obesity is also ele-
vated (73.7%). Education level is low in this population,
as can be seen by the high number (56.5%) of people who
haven't completed Primary School (Brazilian equivalent
to elementary and middle school) and the considerable
illiteracy rate (6.5%).
There were 1286 women who responded positively to one
of the high genetic risk questions in the cross-sectional
study, 902 of whom were further referred to genetic cancer
risk assessment sessions. Of these, 214 had a pedigree sug-
gestive of a hereditary breast cancer predisposition syn-
drome. Preliminary results from the genetic evaluation
have been published elsewhere [17].
Incidence of cancer so far has been 117 cases per 100,000
person-years (9 cases over 7,656 person-years), a number
very similar to the number of cases predicted in the city for
the year 2008, 119 cases per 100,000 women. Compli-
ance to the annual screening has been approximately 60%
so far, and the rate of participants who had their last mam-
mogram not more than 2 years ago is almost 80% [25] (a
more detailed discussion of the adherence to the program
will be published shortly).
Discussion
In this article, we describe the main characteristics of the
NMPOA project, which was designed to test a model of
breast cancer screening and early treatment in an unders-
erved population of a developing country. Also, we aim to
evaluate the prevalence of risk factors for breast cancer in
this population, which is a representative sample of our
city and presents a high breast cancer incidence. The first
important finding of the study was the low rate of patient
inclusion in the cross-sectional study, especially in the age
group which was the target of the screening cohort (25%
of eligible women in the region). Although we cannot be
sure about the total number of women reached by the
active and passive search, this number suggests a low
adherence to preventive health care in this population.
This is in accordance with national data, which showed
that almost 50% of women above 50 years old have never
done mammography, and almost 10% had done their last
exam three or more years before [12].
The incidence of breast cancer in this population is high,
being comparable to developed countries and largely
exceeding the Brazilian average incidence of 51 cases perPage 5 of 8
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we confront it with the baseline data of our cohort: the
majority of breast cancer risk factors in this population
have a low prevalence (such as low hormone replacement
therapy use, low number of pregnancies and a young age
at first delivery), fostering the idea that unknown risk fac-
tors might be playing a major role in this region and rein-
forcing the importance of understanding the distribution
of breast cancer risk factors in different populations. The
incidence of cancer observed so far in the screening cohort
suggests that this sample is representative of our city.
Our longitudinal collection of risk factor data, especially
the genetic risk factors, is very important for an accurate
measurement, since this factor can change over time, as
new information about cancer development in relatives of
the patient becomes acknowledged. The design and sam-
ple size of our study will probably be sufficient to respond
the primary question of our study, regarding the effective-
ness of the model. However, we recognize that the corre-
lation of risk factors and breast cancer will probably be
underpowered. Nevertheless, we believe that our study
can contribute with others in the field, and, in a pooled
analysis through meta-analytic techniques, help us under-
stand the high incidence of the disease in a large area in
our country.
We consider that the high rate of compliance so far is one
the main strengths of your study. This is achieved by
patient education, with information about the impor-
tance of the screening program, and intense contact with
the BHUs, with provision of lists of patients who should
come next month. We also supply transportation for
women with very low financial resources, what helps to
keep attendance. Every three or four months, we select a
region with important problems of attendance and pro-
vide a special bus to take them to the PABHC.
This project aims to establish a model of breast health
attention directed to underserved women that rely only
Table 1: Baseline cohort characteristics
Variable N (%)












Between 1 and 7 years of schooling 2.238 56.5%
Between 8 and 11 years of schooling 1.380 34.9%






Age at first delivery (yrs)* 21.4 ± 5.1
Menopause after 55 yrs old† 88 4.4%
Menarche before 12 yrs old 872 21.6%
History of HRT use 485 12.0%
History of OC use 3,331 82.5%
Smoking status
Current smoker 1,170 29.0%
Former smoker 393 9.7%
No historry 2,474 61.3%
First-degree relative with history of cancer (any site) 1,395 33.7%
First-degree relative with history of breast or ovary cancer 248 6.1%
Previous breast biopsy 154 3.8%
HRT = Hormone Replacement Therapy, OC = Oral Contraceptives
* expressed as mean ± standart deviation; † percentage over 2,002 women who already entered menopausePage 6 of 8
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BMC Public Health 2009, 9:83 http://www.biomedcentral.com/1471-2458/9/83on health care provided by the public sector. The prompt
access of women in our study to the reference service, as
well as the clinical exam done by a specialized profes-
sional and high quality mammography are fundamental
issues for early diagnosis of breast cancer. This is a major
step to reduce breast cancer mortality worldwide.
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